Literature DB >> 21361912

Enhanced lymphocyte interferon (IFN)-γ responses in a PTEN mutation-negative Cowden disease kindred.

R Stevenson1, A Fatehullah, I Jagan, R K Deevi, V Bingham, A E Irvine, M Armstrong, P J Morrison, I Dimmick, R Stewart, F C Campbell.   

Abstract

Identification of immune modifiers of inherited cancer syndromes may provide a rationale for preventive therapy. Cowden disease (CD) is a genetically heterogeneous inherited cancer syndrome that arises predominantly from germline phosphatase and tensin homologue deleted on chromosome 10 (PTEN) mutation and increased phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) signalling. However, many patients with classic CD diagnostic features are mutation-negative for PTEN (PTEN M-Neg). Interferon (IFN)-γ can modulate the PI3K/mTOR pathway, but its association with PTEN M-Neg CD remains unclear. This study assessed IFN-γ secretion by multi-colour flow cytometry in a CD kindred that was mutation-negative for PTEN and other known susceptibility genes. Because IFN-γ responses may be regulated by killer cell immunoglobulin-like receptors (KIR) and respective human leucocyte antigen (HLA) ligands, KIR/HLA genotypes were also assessed. Activating treatments induced greater IFN-γ secretion in PTEN M-Neg CD peripheral blood lymphocytes versus healthy controls. Increased frequency of activating KIR genes, potentially activating KIR/HLA compound genotypes and reduced frequency of inhibitory genotypes, were found in the PTEN M-Neg CD kindred. Differences of IFN-γ secretion were observed among PTEN M-Neg CD patients with distinct KIR/HLA compound genotypes. Taken together, these findings show enhanced lymphocyte secretion of IFN-γ that may influence the PI3K/mTOR CD causal molecular pathway in a PTEN mutation-negative CD kindred.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21361912      PMCID: PMC3087912          DOI: 10.1111/j.1365-2249.2011.04336.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

Review 1.  Biology and clinical relevance of human natural killer cells.

Authors:  M J Robertson; J Ritz
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

2.  A human killer inhibitory receptor specific for HLA-A1,2.

Authors:  C Döhring; D Scheidegger; J Samaridis; M Cella; M Colonna
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

3.  Stimulation of murine natural killer (NK) cells by a monoclonal antibody specific for the NK1.1 antigen. IL-2-activated NK cells possess additional specific stimulation pathways.

Authors:  F M Karlhofer; W M Yokoyama
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

4.  Mechanisms of T cell activation by the calcium ionophore ionomycin.

Authors:  T Chatila; L Silverman; R Miller; R Geha
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

5.  A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase Cepsilon, and MAPK in mesangial cells regulates interferon-gamma-induced STAT1alpha transcriptional activation.

Authors:  Goutam Ghosh Choudhury
Journal:  J Biol Chem       Date:  2004-04-13       Impact factor: 5.157

6.  Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway.

Authors:  Xiao-Ping Zhou; Kristin A Waite; Robert Pilarski; Heather Hampel; Magali J Fernandez; Cindy Bos; Majed Dasouki; Gerald L Feldman; Lois A Greenberg; Jennifer Ivanovich; Ellen Matloff; Annette Patterson; Mary Ella Pierpont; Donna Russo; Najah T Nassif; Charis Eng
Journal:  Am J Hum Genet       Date:  2003-07-03       Impact factor: 11.025

7.  Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry.

Authors:  I Schmid; W J Krall; C H Uittenbogaart; J Braun; J V Giorgi
Journal:  Cytometry       Date:  1992

8.  Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002.

Authors:  S G E Marsh; P Parham; B Dupont; D E Geraghty; J Trowsdale; D Middleton; C Vilches; M Carrington; C Witt; L A Guethlein; H Shilling; C A Garcia; K C Hsu; H Wain
Journal:  Tissue Antigens       Date:  2003-07

9.  Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes.

Authors:  A D'Andrea; C Chang; K Franz-Bacon; T McClanahan; J H Phillips; L L Lanier
Journal:  J Immunol       Date:  1995-09-01       Impact factor: 5.422

10.  The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor.

Authors:  J E Gumperz; V Litwin; J H Phillips; L L Lanier; P Parham
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.